

Dated: April 24, 2025.

**Grace R. Graham,**

*Deputy Commissioner for Policy, Legislation,  
and International Affairs.*

[FR Doc. 2025–07592 Filed 4–30–25; 8:45 am]

**BILLING CODE 4164–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2024–N–4754]

#### Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Financial Disclosure by Clinical Investigators

**AGENCY:** Food and Drug Administration,  
HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug  
Administration (FDA) is announcing  
that a proposed collection of

information has been submitted to the  
Office of Management and Budget  
(OMB) for review and clearance under  
the Paperwork Reduction Act of 1995.

**DATES:** Submit written comments  
(including recommendations) on the  
collection of information by June 2,  
2025.

**ADDRESSES:** To ensure that comments on  
the information collection are received,  
OMB recommends that written  
comments be submitted to [https://  
www.reginfo.gov/public/do/PRAMain](https://www.reginfo.gov/public/do/PRAMain).  
Find this particular information  
collection by selecting “Currently under  
Review—Open for Public Comments” or  
by using the search function. The OMB  
control number for this information  
collection is 0910–0396. Also include  
the FDA docket number found in  
brackets in the heading of this  
document.

**FOR FURTHER INFORMATION CONTACT:**  
Amber Sanford, Office of Operations,  
Food and Drug Administration, Three  
White Flint North, 10A–12M, 11601

Landsdown St., North Bethesda, MD  
20852, 301–796–8867, [PRAStaff@  
fda.hhs.gov](mailto:PRAStaff@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** In  
compliance with 44 U.S.C. 3507, FDA  
has submitted the following proposed  
collection of information to OMB for  
review and clearance.

#### Financial Disclosure by Clinical Investigators

*OMB Control Number 0910–0396—  
Extension*

Respondents to this collection are  
sponsors of marketing applications that  
contain clinical data from studies  
covered by the regulations. These  
sponsors represent pharmaceutical,  
biologic, and medical device firms.  
Respondents are also clinical  
investigators who provide financial  
information to the sponsors of  
marketing applications.

Table 1 shows information that is the  
basis of the estimated number of  
respondents in tables 2 through 4.

TABLE 1—ESTIMATED NUMBER OF APPLICATIONS, CLINICAL TRIALS, AND INVESTIGATORS SUBJECT TO THE REGULATION  
BY TYPE OF APPLICATION <sup>1</sup>

Application type	Total number of applications	Number of applications affected	Number of trials	Number of investigators
Drugs:				
New drug application (NDA), new molecular entity (NME) .....	35	35	3 to 10 .....	3 to 100.
NDA non-NME .....	94	44	3 to 10 .....	3 to 100.
NDA efficacy supplement .....	171	100	1 to 3 .....	10 to 30.
Abbreviated new drug application (ANDA) .....	685	1	1.1 .....	2.
ANDA supplement .....	10,366	1	1 .....	2.
CBER Biologics:				
Biologics license application (BLA) .....	26	26	3 to 10 .....	3 to 100.
BLA efficacy supplement .....	26	26	1 to 3 .....	10 to 30.
CDER Biologics:				
BLAs .....	19	19	3 to 10 .....	3 to 100.
BLA efficacy supplements .....	64	50	1 to 3 .....	10 to 30.
Medical Devices:				
Premarket approval (PMA) .....	43	50	1 to 31 .....	10 to 20.
PMA supplement .....	28	30	to 3 .....	3 to 10
Reclassification devices .....	0	0	0 .....	0.
510(k) .....	3,401	254	1 .....	3 to 10.
De Novo requests .....	84	76	1 to 3 .....	10 to 20.

<sup>1</sup> Source: Agency estimates.

FDA estimates the burden of this  
collection of information as follows:

#### Reporting Burden

Under § 54.4(a) (21 CFR 54.4(a)),  
applicants submitting an application  
that relies on clinical studies must  
submit a complete list of clinical  
investigators who participated in a  
covered clinical study, and must either  
certify to the absence of certain financial  
arrangements with clinical investigators  
(Form FDA 3454) or, under § 54.4(a)(3),  
disclose to FDA the nature of those

arrangements and the steps taken by the  
applicant or sponsor to minimize the  
potential for bias (Form FDA 3455).

FDA estimates that almost all  
applicants submit a certification  
statement under § 54.4(a)(1) and (2).  
Preparation of the statement using Form  
FDA 3454 should require no more than  
1 hour per study. The number of  
respondents is based on the estimated  
number of affected applications.

When certification is not possible and  
disclosure is made using Form FDA  
3455, the applicant must describe,

under § 54.4(a)(3), the financial  
arrangements or interests and the steps  
that were taken to minimize the  
potential for bias in the affected study.  
As the applicant would be fully aware  
of those arrangements and the steps  
taken to address them, describing them  
will be straightforward. The Agency  
estimates that it will take about 5 hours  
to prepare this narrative. Based on our  
experience with this collection, FDA  
estimates that approximately 10 percent  
of the respondents with affected

applications will submit disclosure statements.

In the **Federal Register** of November 29, 2024 (89 FR 94735), FDA published

a 60-day notice requesting public comment on the proposed collection of information. One comment was received but was not PRA related.

FDA estimates the burden of this collection of information as follows:

TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN <sup>1</sup>

21 CFR section	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
Certification—54.4(a)(1) and (2)—Form FDA 3454 .....	712	1	712	1	712
Disclosure—54.4(a)(3)—Form FDA 3455 .....	71	1	71	5	355
Total .....					1,067

<sup>1</sup> There are no capital costs or operating and maintenance costs associated with this collection of information.

#### Recordkeeping Burden

Under § 54.6 (21 CFR 54.6), the sponsors of covered studies must maintain complete records of compensation agreements with any compensation paid to nonemployee

clinical investigators, including information showing any financial interests held by the clinical investigator, for 2 years after the date of approval of the applications. Sponsors of covered studies maintain many records regarding clinical investigators,

including protocol agreements and investigator resumes or curriculum vitae. FDA estimates an average of 15 minutes will be required for each recordkeeper to add this record to the clinical investigators' file.

TABLE 3—ESTIMATED ANNUAL RECORDKEEPING BURDEN <sup>1</sup>

21 CFR section	Number of recordkeepers	Number of records per recordkeeper	Total annual records	Average burden per recordkeeping	Total hours <sup>2</sup>
Recordkeeping—54.6 .....	712	1	712	0.25	178

<sup>1</sup> There are no capital costs or operating and maintenance costs associated with this collection of information.

<sup>2</sup> Numbers have been rounded.

#### Third-Party Disclosure Burden

Under § 54.4(b), clinical investigators supply to the sponsor of a covered study financial information sufficient to allow the sponsor to submit complete and accurate certification or disclosure statements. Clinical investigators are accustomed to supplying such information when applying for research

grants. Also, most people know the financial holdings of their immediate family and records of such interests are generally accessible because they are needed for preparing tax records. For these reasons, FDA estimates that the time required for this task may range from 5 to 15 minutes; we used the median, 10 minutes, for the average burden per disclosure (see table 4). To

estimate the number of respondents for each FDA Center, we took the median number of investigators for each application type, multiplied each median number of investigators by the number of affected applications for that application type, then summed those products to get the total number of respondents for the Center.

TABLE 4—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN <sup>1</sup>

21 CFR section	Number of respondents	Number of disclosures per respondent	Total annual disclosures	Average burden per disclosure	Total hours <sup>2</sup>
54.4(b)—Clinical Investigators .....	13,646	1	13,646	0.17	2,320

<sup>1</sup> There are no capital costs or operating and maintenance costs associated with this collection of information.

<sup>2</sup> Numbers have been rounded.

The burden for this information collection request has changed since the last OMB approval. We have adjusted our estimated burden for the information collection to reflect the

number of submissions we received in the last few years. These adjustments result in an increase of 557 total annual responses and a corresponding increase of 87 total hours.

Dated: April 24, 2025.

**Grace R. Graham,**  
Deputy Commissioner for Policy, Legislation,  
and International Affairs.

[FR Doc. 2025-07577 Filed 4-30-25; 8:45 am]

BILLING CODE 4164-01-P